慢性脊髓损伤成人阿片类与苯二氮䓬类药物使用:自我报告与州处方监测数据的一致性
本研究基于美国东南部州人群脊髓损伤登记库,纳入345名慢性脊髓损伤成人,比较自我报告的阿片类与苯二氮䓬类药物使用与处方监测程序(PMP)配药记录,评估潜在低报程度。结果显示自我报告与配药记录总体一致性较高,仅少数药物存在极低比例的低报,支持在脊髓损伤人群中采用自我报告评估这类处方药使用。
要点
- 脊髓损伤成人自我报告阿片类与苯二氮䓬类药物使用与处方监测数据一致性较高。
- 仅11%匹配个体低报阿片类(≥2次配药),1%低报苯二氮䓬类。
- 支持在脊髓损伤人群中使用自我报告评估这类处方药使用。
核心结论
- 自我报告与配药记录在阿片类和苯二氮䓬类药物使用上一致性较高,潜在低报极少,支持脊髓损伤人群自我报告此类处方药使用的适宜性。
研究设计与样本
- 横断面自我报告评估结合处方监测程序数据回顾性审查,纳入345名大于18岁、慢性脊髓损伤超过1年的社区居住成人。
主要发现
- 345名参与者中252名可匹配到处方监测数据;匹配个体中11%低报阿片类(≥2次配药),1%低报苯二氮䓬类。
- 各阿片类药物低报率范围为0.4%至4%,涉及氢可酮、羟考酮、曲马多、可待因、丁丙诺啡和氢吗啡酮;芬太尼、羟吗啡酮、哌替啶和美沙酮自我报告与配药记录完全一致。
- 苯二氮䓬类潜在低报率低于2%。
关键数值与推荐
- 低报定义为自我报告过去一年「从未」使用阿片类或苯二氮䓬类,但在自我报告评估前一年内有2次或以上相应处方配药。
临床怎么用
- 在脊髓损伤人群中,临床可参考自我报告评估阿片类与苯二氮䓬类药物使用情况,但需注意少数药物存在低报可能。
局限性
- 未匹配到处方监测数据的参与者原因包括未在州内配取管制药品处方或处方在州外配取,可能影响结果代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare self-reported opioid and benzodiazepine use to rates of prescriptions dispensed among persons with chronic spinal cord injury (SCI), to evaluate the extent of potential underreporting. DESIGN: Cross-sectional self-report assessment (SRA) and retrospective review of prescription monitoring program (PMP) data. SETTING: Community dwelling adults in the Southeastern United States. PARTICIPANTS: In total, 345 adults (N=345) (>18y) with chronic (>1y) SCI who were identified through a state population-based SCI registry and who responded to SRA opioid use questions in a parent study. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Self-reported prescription pain reliever, sedative, and tranquilizer use, and prescriptions dispensed based on PMP data. We compared self-reported past year utilization with records of dispensed prescriptions to assess potential underreporting, defined as reporting "never" using either opioids (pain relievers) or benzodiazepines (sedatives/tranquilizers) in the past year, but having had 2 or more respective prescriptions dispensed in the year before the SRA. RESULTS: Among the 345 participants who responded to the opioid use questions, we were able to match 252 to the PMP; reasons for not matching include not filling a controlled substance prescription in-state, either because of lack of reportable prescriptions or the prescription was dispensed out of state. Evaluating each prescription medication, rates of underreporting for each drug ranged from 0.4% to 4% for hydrocodone, oxycodone, tramadol, codeine, buprenorphine, and hydromorphone. There was 100% agreement in the self-reported use and dispensed records for fentanyl, oxymorphone, meperidine, and methadone. The rates of potential underreporting of benzodiazepines were <2%. Overall, of the 252 matched individuals, 11% underreported opioids (2 or more prescriptions dispensed) and 1% underreported benzodiazepines. CONCLUSIONS: The findings suggest considerable agreement between self-reported and dispensed prescription medication use, and only minimal potential underreporting of select opioids and benzodiazepines, confirming the appropriateness of self-report of these prescription medications with people with SCI.
引用
- DiPiro ND, Murday D, Donnelly S, et al. Opioid and Benzodiazepine Use Among a Population-Based Cohort of Adults With Chronic Spinal Cord Injury: Correspondence Between Self-report and State Prescription Monitoring Data. Arch Phys Med Rehabil. 2025. PMID: 40374055. doi:10.1016/j.apmr.2025.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。